Companies expect vaccination for this age group to begin before the next school year.
Phase 3 trials conducted on 2,260 teenagers in the United States “demonstrated 100% efficacy and robust antibody responses,” the companies said in a statement.
American Pfizer and German BioNTech will now submit the data to different regulatory authorities around the world, “in the hope of starting to vaccinate this age group at the beginning of next school year,” said Albert Bourla, director-general of the North American pharmaceutical laboratory.
On the part of the German laboratory, Ugur Sahin considered that the results for the 12 to 15 age group are “very encouraging, taking into account the trend observed in recent weeks regarding the spread” of the virus variant initially detected in the United Kingdom.
The Pfizer / BioNTech vaccine, based on innovative messenger RNA (mRNA) technology, was the first vaccine against covid-19 approved in the west in late 2020.
The United States and the European Union have authorized use for persons aged 16 and over.
So far, the vaccine has been used in millions of adults over the age of 65.
A study carried out on 1.2 million people in Israel demonstrated 94% effectiveness.
Children are less prone to severe cases of the disease, so vaccination is not a priority at this time.
Get the latest news delivered to your inbox
Follow us on social media networks